Amarantus Bioscience Holdings Inc (AMBS)

[Voices of Reason]

Regarding the paid tout by Tomorrowsbluechips.com, here is my take:

The analyst report states: "The most extreme example includes GlaxoSmithKline's (GSK) $57M buyout of Genelabs (GNLB) for an astounding premium of over 400% for the latter's hepatitis C clinical development assets" - yet without any basis for supporting their prediction, they tout a target price for AMBS at $0.10 to $0.15 - an astonishing potential increase of 669% to 1054% from the stated stock price of $0.013 (currently at $0.0099) - several fold above their "extreme" example for GNLB.

I suppose this is not so surprising considering their disclaimer which states: "TomorrowsBlueChips parent company Seraphim Holdings llc has been compensated for coverage/awareness efforts the following companies: Amarantus BioSciences Inc. AMBS) – 2,319,999 restricted shares and 50,000 free trading shares for 6 months services expiring 5/24/12. 75,755 AMBS open market purchase, which position has been closed. AMBS.BB compensation 225,000 restricted shares for 30 days marketing / awareness services on May 9 2012."

What is curious is that their services appear to have expired on 5/24/12 - which leads me to believe that the remaining 2.5 million restricted shares have now come off of restriction and they are pumping this one more time to cash out.